All In Biotech

Drug Trial Radar · NCT03182907

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)

Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

148

Actual

Start

Mar 27, 2018

Primary completion

May 12, 2022

Study completion May 12, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab (MK-6072) in children aged 1 to \<18 years of age with a confirmed diagnosis of Clostridium difficile infection (CDI) who are receiving antibacterial drug treatment. The primary hypothesis is that the area under the concentration-time curve from 0 to infinity (AUC0-inf) of bezlotoxumab after treatment of pediatric participants with bezlotoxumab is similar when compared to the AUC0-inf of bezlotoxumab after treatment of adults with bezlotoxumab.

Conditions

  • Clostridium Difficile Infection

Interventions

  • BezlotoxumabBiological

    A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.

  • PlaceboDrug

    A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.

  • Antibacterial drug treatment (ABD)Drug

    ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve of Bezlotoxumab From Time 0 to Infinity (AUC0-inf)Time frame: Day 1 (2 hours postdose), Days 10, 29, 57, and 85
  2. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 12 weeks
  3. Percentage of Participants Who Discontinued Study Due to an AETime frame: Up to approximately 12 weeks

Locations

75 sites in 17 countries. Site status is shown where the registry gives one.

  • Children's Hospital - Los Angeles ( Site 0021)

    Los Angeles, California

  • UCSF Medical Center ( Site 0049)

    San Francisco, California

  • Children's Hospital - Colorado ( Site 0013)

    Aurora, Colorado

  • Children's Center for Digestive Healthcare ( Site 0052)

    Atlanta, Georgia

  • University of Chicago ( Site 0019)

    Chicago, Illinois

  • Our Lady of the Lake Hospital ( Site 0007)

    Baton Rouge, Louisiana

  • The Johns Hopkins Rubenstein Child Health Building ( Site 0034)

    Baltimore, Maryland

  • Tufts Medical Center-Floating Hospital for Children ( Site 0046)

    Boston, Massachusetts

  • Mayo Clinic - Rochester ( Site 0004)

    Rochester, Minnesota

  • Washington University ( Site 0037)

    St Louis, Missouri

  • Columbia University Medical Center/ MSCHONY ( Site 0042)

    New York, New York

  • SUNY Upstate Medical Center, University Hospital ( Site 0027)

    Syracuse, New York

  • Montefiore Einstein Center ( Site 0041)

    The Bronx, New York

  • Duke University Health System ( Site 0025)

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center ( Site 0024)

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center ( Site 0029)

    Cleveland, Ohio

  • St. Jude Children's Research Hospital ( Site 0050)

    Memphis, Tennessee

  • Vanderbilt University Medical Center ( Site 0022)

    Nashville, Tennessee

  • The Children's Hospital of San Antonio ( Site 0009)

    San Antonio, Texas

  • Primary Children's Hospital ( Site 0001)

    Salt Lake City, Utah

  • Seattle Childrens Hospital ( Site 0028)

    Seattle, Washington

  • Hospital Privado de Cordoba ( Site 2102)

    Córdoba, Argentina

  • Hospital Italiano de Buenos Aires. ( Site 2103)

    Caba, Buenos Aires, Argentina

  • Instituto de Oncologia Pediatrica - GRAACC - Unifesp ( Site 0205)

    São Paulo, Brazil

  • Santa Casa de Misericordia de Belo Horizonte ( Site 0208)

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Clinicas da Universidade Federal do Parana ( Site 0203)

    Curitiba, Paraná, Brazil

  • Hospital Pequeno Principe ( Site 0200)

    Curitiba, Paraná, Brazil

  • Hospital Universitario da Universidade Federal de Santa Maria ( Site 0209)

    Santa Maria, Rio Grande do Sul, Brazil

  • Hospital Pablo Tobon Uribe-Infectology pediatric ( Site 2166)

    Medellín, Antioquia, Colombia

  • Fundacion Santa Fe de Bogota ( Site 2167)

    Bogotá, Bogota D.C., Colombia

  • Fundacion Cardioinfantil Instituto de Cardiologia ( Site 2163)

    Bogotá, Bogota D.C., Colombia

  • Fundacion Valle del Lili ( Site 2161)

    Cali, Valle del Cauca Department, Colombia

  • Centro Medico Imbanaco ( Site 2160)

    Cali, Valle del Cauca Department, Colombia

  • 2. LF UK a FN Motol ( Site 2003)

    Prague, Czechia

  • Fakultni Nemocnice Brno Bohunice ( Site 2000)

    Brno, Brno-mesto, Czechia

  • Fakultni nemocnice Plzen ( Site 2001)

    Plzen Lochotin, Plzeň Region, Czechia

  • Universitaetsklinikum Hamburg Eppendorf ( Site 1402)

    Hamburg, Germany

  • Universitaetsklinikum Muenster ( Site 1400)

    Münster, North Rhine-Westphalia, Germany

  • Semmelweis University-II.sz. Gyermekgyógyászati Klinika ( Site 2201)

    Budapest, Hungary

  • Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet ( Site 2202)

    Budapest, Hungary

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.